ZURA BIO LTD (ZURA) Stock Price & Overview
NASDAQ:ZURA • KYG9TY5A1016
Current stock price
The current stock price of ZURA is 6.03 USD. Today ZURA is down by 0%. In the past month the price decreased by -10.8%. In the past year, price increased by 485.44%.
ZURA Key Statistics
- Market Cap
- 519.907M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.06
- Dividend Yield
- N/A
ZURA Stock Performance
ZURA Stock Chart
ZURA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ZURA. When comparing the yearly performance of all stocks, ZURA is one of the better performing stocks in the market, outperforming 99.02% of all stocks.
ZURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZURA. ZURA has a great financial health rating, but its profitability evaluates not so good.
ZURA Earnings
ZURA Forecast & Estimates
14 analysts have analysed ZURA and the average price target is 16.17 USD. This implies a price increase of 168.23% is expected in the next year compared to the current price of 6.03.
ZURA Groups
Sector & Classification
ZURA Financial Highlights
Over the last trailing twelve months ZURA reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS decreased by -92.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.19% | ||
| ROE | -97.85% | ||
| Debt/Equity | 0 |
ZURA Ownership
ZURA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZURA
Company Profile
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Company Info
IPO: 2021-07-16
ZURA BIO LTD
4225 Executive Square, Suite 600
La Jolla CALIFORNIA US
Employees: 30
Phone: 18582470520
ZURA BIO LTD / ZURA FAQ
Can you describe the business of ZURA BIO LTD?
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
What is the stock price of ZURA BIO LTD today?
The current stock price of ZURA is 6.03 USD.
Does ZURA stock pay dividends?
ZURA does not pay a dividend.
What is the ChartMill rating of ZURA BIO LTD stock?
ZURA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for ZURA stock?
ZURA BIO LTD (ZURA) currently has 30 employees.
What is the market capitalization of ZURA stock?
ZURA BIO LTD (ZURA) has a market capitalization of 519.91M USD. This makes ZURA a Small Cap stock.